Since neither cure nor treatment to alter the progression of AD has been observed until now (Athar et al., 2021), alternative strategies could be therefore to develop agonists that can simultaneously activate PPARα and PPARγ such as fenofibrate and diosmetin and/or inhibit ACAT activity such as naringenin. The gene discussed is PPARA; the disease is Alzheimer disease.